- Home
- IHS vs IRON Comparison
IHS vs IRON Comparison
Compare IHS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IHS | IRON |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IHS | IRON |
|---|---|---|
| Price | $8.46 | $67.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 11 |
| Target Price | $8.29 | ★ $103.18 |
| AVG Volume (30 Days) | ★ 1.3M | 432.9K |
| Earning Date | 05-19-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.26 | N/A |
| Revenue Next Year | $7.87 | $283.52 |
| P/E Ratio | $5.85 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.71 | $40.00 |
| 52 Week High | $8.95 | $99.50 |
Technical Indicators
Market Signals| Indicator | IHS | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 26.37 |
| Support Level | $8.11 | $64.48 |
| Resistance Level | $8.52 | $71.85 |
| Average True Range (ATR) | 0.04 | 3.04 |
| MACD | 0.00 | -1.39 |
| Stochastic Oscillator | 60.00 | 8.69 |
Price Performance
Historical ComparisonAbout IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria and Sub-Saharan Africa. The majority of its revenue is derived from Nigeria.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.